Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17509684 | 0.95 | SCN9A (0.45) | SCN9A | |
| SCHEMBL16100156 | 0.90 | SCN9A (0.48) | SCN9A | |
| SCHEMBL17509689 | 0.90 | SCN9A (0.45) | SCN9A | |
| SCHEMBL1094007 | 0.85 | SCN9A (0.48) | SCN9A | |
| SCHEMBL9924648 | 0.79 | SCN9A (0.45) | SCN9A | |
| SCHEMBL16011228 | 0.77 | SCN9A (0.52) | SCN9A | |
| SCHEMBL10185423 | 0.77 | SCN9A (0.51) | SCN9A | |
| SCHEMBL10185455 | 0.77 | SCN9A (0.49) | SCN9A | |
| SCHEMBL29736477 | 0.76 | SCN9A (0.39) | SCN9A | |
| SCHEMBL28556096 | 0.76 | SCN9A (0.39) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | CHROMOCELL CORPORATION | 2019-01-15 | — | — | US | disclosed |
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | CHROMOCELL CORPORATION | 2019-01-15 | — | — | US | disclosed |
| EP-3043787-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORP (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-2968234-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORP (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2968234-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORP (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3193610-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | Chromocell Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9458118-B2 | Sodium channel modulators for the treatment of pain and diabetes | CHROMOCELL CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458118-B2 | Sodium channel modulators for the treatment of pain and diabetes | CHROMOCELL CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160221974-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-08-04 | — | — | US | disclosed |
| EP-3043787-A2 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | Chromocell Corporation (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-05-12 | — | — | US | disclosed |
| WO-2016040315-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2968234-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Chromocell Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151472-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151472-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221974-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | SCN7A, SCN1A, SCN10A | SCN9A 11/4885 |
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | SCN7A, SCN1A, SCN10A | SCN9A 11/4885 |
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | SCN7A, SCN10A, SCN2A | SCN9A 13/4885 |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | SCN7A, SCN10A, SCN2A | SCN9A 13/4885 |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | SCN7A, SCN1A, SCN1B | SCN9A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.